Journal of Medicinal Chemistry
Article
recombinantly expressed rat and human histamine H3 receptors. Eur.
J. Pharmacol. 2002, 453, 33−41.
ABBREVIATIONS USED
■
CNS, central nervous system; H1R−H4R, H1−H4 receptors;
H3R, H3 receptor; ADHD, attention-deficit hyperactivity dis-
corder; AD, Alzheimer’s disease; SAR, structure−activity
relationship; PK, pharmacokinetics; [3H]NAMH, [3H]N-α-
methylhistamine; [35S]GTPγS, guanosine 5′-(γ-thio)-
triphosphate; RAMH, R-α-methylhistamine; hERG, human
ether-a-go-go-related gene; SR, social recognition
(4) Raddatz, R.; Tao, M.; Hudkins, R. L. Histamine H3 antagonists
for treatment of cognitive deficits in CNS diseases. Curr. Top. Med.
Chem. 2010, 10, 153−169.
(5) Hudkins, R. L.; Raddatz, R.; Tao, M.; Mathiasen, J. R.; Aimone,
L. D.; Becknell, N. C.; Prouty, C. P.; Knutsen, L.; Yazdanian, M.;
Moachon, G.; Ator, M. A.; Mallamo, J. P.; Marino, M. J.; Bacon, E. R.;
Williams, M. Discovery and characterization of 6-{4-[3-(R)-
methylpyrrolidin-1-yl)-propoxy]phenyl}-2H-pyridazin-3-one (CEP-
26401, irdabisant): a potent, selective histamine H3 receptor inverse
agonist. J. Med. Chem. 2011, 54, 4781−4792.
(6) (a) Wermuth, C. G.; Schlewer, G.; Bourguignon, J. J.; Maghioros,
G.; Bouchet, M. J.; Moire, C.; Kan, J. P.; Worms, P.; Biziere, K. 3-
Aminopyridazine derivatives with atypical antidepressant, serotonergic,
and dopaminergic activities. J. Med. Chem. 1989, 32, 528−537.
(b) Coates, W. J.; McKillop, A. One-pot preparation of 6-substituted
3(2H)-pyridazinones from ketones. Synthesis 1993, 334−342.
(7) Sugahara, M.; Ukita, T. A facile copper-catalyzed Ullmann
condensation: N-arylation of heterocyclic compounds containing an
-NHCO- moiety. Chem. Pharm. Bull. 1997, 45, 719−721.
(8) Bacon, E. R.; Bailey, T. R.; Becknell, N. C.; Chatterjee, S.; Dunn,
D.; Hostetler, G. A.; Hudkins, R. L.; Josef, K. A.; Knutsen, L.; Tao, M.;
Zulli, A. L. Pyridazinone Derivatives. US2010273779, 2010.
(9) (a) Ploemen, J. P.; Kelder, J.; Hafmans, T.; van de Sandt, H.; van
Burgsteden, J A.; Saleminki, P. J.; van Esch, E. Use of physicochemical
calculation of pKa and ClogP to predict phospholipidosis-inducing
potential: a case study with structurally related piperazine. Exp. Toxicol.
Pathol. 2004, 55, 347−355. (b) Reasor, M. J.; Hastings, K. L.; Ulrich,
R. G. Drug-induced phospholipidosis: issues and future directions.
Expert Opin. Drug Saf. 2006, 5, 567−583.
(10) Raucy, J.; Warfe, L.; Yueh, M. F.; Allen, S. W. A cell-based
reporter gene assay for determining induction of CYP3A4 in a high-
volume system. J. Pharmacol. Exp. Ther. 2002, 303, 412−423.
(11) Summerfield, S. G.; Stevens, A. J.; Cutler, L.; del Carmen
Osuna, M.; Hammond, B.; Tang, S. P.; Hersey, A.; Spalding, D. J.;
Jeffrey, P. Improving the in vitro prediction of in vivo central nervous
system penetration: integrating permeability, P-glycoprotein efflux,
and free fractions in blood and brain. J. Pharmacol. Exp. Ther. 2006,
316, 1282−1290.
(12) (a) Clapham, J.; Kilpatrick, G. J. Histamine H3 receptor-
mediated modulation of water consumption in the rat. Eur. J.
Pharmacol. 1993, 232, 99−103. (b) Medhurst, A. D.; Atkins, A. R.;
Beresford, I. J.; Brackenborough, K.; Briggs, M. A.; Calver, A. R.; Cilia,
J.; Cluderay, J. E.; Crook, B.; Davis, J. B.; Davis, R. K.; Davis, R. P.;
Dawson, L. A.; Foley, A. G.; Gartlon, J.; Gonzalez, M. I.; Heslop, T.;
Hirst, W. D.; Jennings, C.; Jones, D. N.; Lacroix, L. P.; Martyn, A.;
Ociepka, S.; Ray, A.; Regan, C. M.; Roberts, J. C.; Schogger, J.;
Southam, E.; Stean, T. O.; Trail, B. K.; Upton, N.; Wadsworth, G.;
Wald, J. A.; White, T.; Witherington, J.; Woolley, M. L.; Worby, A.;
Wilson, D. M. GSK189254, a novel H3 receptor antagonist that binds
to histamine H3 receptors in Alzheimer’s disease brain and improves
cognitive performance in preclinical models. J. Pharmacol. Exp. Ther.
2007, 321, 1032−1045. (c) Lecklin, A.; Etu-Seppala, P.; Stark, H.;
Tuomisto, L. Effects of intracerebroventricularly infused histamine and
selective H1, H2 and H3 agonists on food and water intake and urine
flow in Wistar rats. Brain Res. 1998, 793, 279−288.
(13) (a) Thor, D.; Holloway, W. Social memory of the
male laboratory rat. J. Comp. Physiol. Psychol 1982, 96, 1000−1006.
(b) Raddatz, R.; Hudkins, R. L.; Mathiasen, J. R.; Gruner, J. A.; Flood,
D. G.; Aimone, L. D.; Le, S.; Schaffhauser, H.; Gasior, M.; Bozyczko-
Coyne, D.; Marino, M. J.; Ator, M. A.; Bacon, E. R.; Mallamo, J. P.;
Williams, M. CEP-26401 (irdabisant), a potent and selective histamine
H3 receptor antagonist/inverse agonist with cognition-enhancing and
wake promoting activities. J. Pharmacol. Exp. Ther. [Online early
access]. DOI: 10.1124/jpet.111.186585. Published Online: Oct 14,
2011.
REFERENCES
■
(1) Reviews: (a) Berlin, M.; Boyce, C. W.; de Lera Ruiz, M.
Histamine H3 receptor as a drug discovery target. J. Med. Chem. 2011,
54, 26−53. (b) Brown, R. E.; Stevens, D. R.; Haas, H. L. The
physiology of brain histamine. Prog. Neurobiol. 2001, 63, 637−672.
(c) Cowart, M. D.; Altenbach, R.; Black, L.; Faghih, R.; Zhao, C.;
Hancock, A. A. Medicinal chemistry and biological properties of non-
imidazole histamine H3 antagonists. Mini-Rev. Med. Chem. 2004, 979−
992. (d) Leurs, R.; Bakker, R. A.; Timmerman, H.; de Esch, I. J. The
histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat.
Rev. Drug Discovery 2005, 4, 107−120. (e) Wijtmans, M.; Leurs, R.; de
Esch, I. Histamine H3 receptor ligands break ground in a remarkable
plethora of therapeutic areas. Expert Opin. Invest. Drugs. 2007, 16,
967−985. (f) Esbenshade, T. A.; Fox, G. B.; Cowart, M. D. Histamine
H3 receptor antagonists: preclinical promise for treating obesity and
cognitive disorders. Mol. Interventions 2006, 6, 77−88. (g) Esbenshade,
T. A.; Browman, K. E.; Bitner, R. S.; Strakhova, M.; Cowart, M. D.;
Brioni, J. D. Histamine H3 receptor antagonists: preclinical promise for
treating obesity and cognitive disorders. Br. J. Pharmacol. 2008, 154,
1166−1181. (h) Hudkins, R. L.; Raddatz, R. Recent advances in drug
discovery of histamine H3 antagonist. Annu. Rep. Med. Chem. 2007, 42,
49−63. (i) Sander, K.; Kottke, T.; Stark, H. Histamine H3 receptor
antagonists go to clinics. Biol. Pharm. Bull. 2008, 31, 2163−2181.
(2) (a) Oda, T.; Morikawa, N.; Saito, Y.; Masuho, Y.; Matsumoto, S.
Molecular cloning and characterization of a novel type of histamine
receptor preferentially expressed in leukocytes. J. Biol. Chem. 2000,
275, 36781−36786. (b) Liu, C.; Ma, X.; Jiang, X.; Wilson, S. J.;
Hofstra, C. L.; Blevitt, J.; Pyati, J.; Li, X.; Chai, W.; Carruthers, N.;
Lovenberg, T. W. Cloning and pharmacological characterization of a
fourth histamine receptor (H(4)) expressed in bone marrow. Mol.
Pharmacol. 2001, 59, 420−426. (c) Cowart, M. D.; Altenbach, R. J.;
Liu, H.; Hsieh, G. C.; Drizin, I.; Milicic, I.; Miller, T. R.; Witte, D. G.;
Wishart, N.; Fix-Stenzel, S. R.; McPherson, M. J.; Adair, R. M.; Wetter,
J. M.; Bettencourt, B. M.; Marsh, K. C.; Sullivan, J. P.; Honore, P.;
Esbenshade, T. A.; Brioni, J. D. Rotationally constrained 2,4-diamino-
5,6-disubstituted pyrimidines: a new class of histamine H4 receptor
antagonists with improved druglikeness and in vivo efficacy in pain and
inflammation models. J. Med. Chem. 2008, 51, 6547−6557.
(d) Cowart, M. D.; Faghih, R.; Curtis, M. P.; Gfesser, G. A.;
Bennani, Y. L.; Black, L. A.; Pan, L.; Marsh, K. C.; Sullivan, J. P.;
Esbenshade, T. A.; Fox, G. B.; Hancock, A. A. 4-(2-[2-(2(R)-
Methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related
2-aminoethylbenzofuran H3 receptor antagonists potently enhance
cognition and attention. J. Med. Chem. 2005, 48, 38−45. (e) Nagase,
T.; Mizutani, T.; Ishikawa, S.; Sekino, E.; Sasaki, T.; Fujimura, T.; Ito,
S.; Mitobe, Y.; Miyamoto, Y.; Yoshimoto, R.; Tanaka, T.; Ishihara, A.;
Takenaga, N.; Tokita, S.; Fukami, T.; Sato, N. Synthesis, structure−
activity relationships, and biological profiles of a quinazolinone class of
histamine H3 receptor inverse agonists. J. Med. Chem. 2008, 51, 4780−
4789.
(3) (a) Arrang, J. M.; Garbarg, M.; Schwartz, J. C. Auto-inhibition of
brain histamine release mediated by a novel class (H3) of histamine
receptor. Nature 1983, 302, 832−837. (b) Lovenberg, T. W.;
Roland, B. L.; Wilson, S. J.; Jiang, X.; Pyati, J.; Huvar, A.; Jackson,
M. R.; Erlander, M. G. Cloning and functional expression of the
human histamine H3 receptor. Mol. Pharmacol. 1999, 55, 1101−1107.
(c) Bongers, G.; Bakker, R. A.; Leurs, R. Molecular aspects of the
histamine H3 receptor. Biochem. Pharmacol. 2007, 73, 1195−1204.
(d) Wulff, B. S.; Hastrup, S.; Rimvall, K. Characteristics of
(14) Irwin, S. Comprehensive observational assessment: Ia. A
systematic quantitative procedure for assessing the behavioural and
422
dx.doi.org/10.1021/jm201295j | J. Med. Chem. 2012, 55, 414−423